JP2010508847A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010508847A5 JP2010508847A5 JP2009536307A JP2009536307A JP2010508847A5 JP 2010508847 A5 JP2010508847 A5 JP 2010508847A5 JP 2009536307 A JP2009536307 A JP 2009536307A JP 2009536307 A JP2009536307 A JP 2009536307A JP 2010508847 A5 JP2010508847 A5 JP 2010508847A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tes7
- tumor
- carcinoma
- sarcoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 36
- 206010028980 Neoplasm Diseases 0.000 claims 30
- 201000011510 cancer Diseases 0.000 claims 20
- 206010024612 Lipoma Diseases 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- 230000001394 metastastic effect Effects 0.000 claims 11
- 206010061289 metastatic neoplasm Diseases 0.000 claims 11
- 208000003174 Brain Neoplasms Diseases 0.000 claims 8
- 206010009944 Colon cancer Diseases 0.000 claims 8
- 108060003951 Immunoglobulin Proteins 0.000 claims 8
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 8
- 206010038389 Renal cancer Diseases 0.000 claims 8
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 8
- 206010039491 Sarcoma Diseases 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 8
- 102000018358 immunoglobulin Human genes 0.000 claims 8
- 201000010982 kidney cancer Diseases 0.000 claims 8
- 150000007523 nucleic acids Chemical group 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 8
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 8
- 208000008732 thymoma Diseases 0.000 claims 8
- 208000005243 Chondrosarcoma Diseases 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 238000001514 detection method Methods 0.000 claims 6
- 239000003446 ligand Substances 0.000 claims 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 5
- 201000010881 cervical cancer Diseases 0.000 claims 5
- 230000003993 interaction Effects 0.000 claims 5
- 208000030507 AIDS Diseases 0.000 claims 4
- 208000001783 Adamantinoma Diseases 0.000 claims 4
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 claims 4
- 208000019838 Blood disease Diseases 0.000 claims 4
- 206010005949 Bone cancer Diseases 0.000 claims 4
- 208000018084 Bone neoplasm Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 208000001843 Carotid Body Tumor Diseases 0.000 claims 4
- 208000037211 Carotid body tumour Diseases 0.000 claims 4
- 201000009047 Chordoma Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 4
- 206010014967 Ependymoma Diseases 0.000 claims 4
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 4
- 208000021309 Germ cell tumor Diseases 0.000 claims 4
- 208000009164 Islet Cell Adenoma Diseases 0.000 claims 4
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 208000000172 Medulloblastoma Diseases 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 4
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 4
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 4
- 208000000035 Osteochondroma Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 4
- 206010033963 Parathyroid tumour Diseases 0.000 claims 4
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims 4
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 4
- 206010057644 Testis cancer Diseases 0.000 claims 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 4
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 4
- 230000000890 antigenic effect Effects 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 4
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 4
- 208000009060 clear cell adenocarcinoma Diseases 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 claims 4
- 201000011523 endocrine gland cancer Diseases 0.000 claims 4
- 230000003352 fibrogenic effect Effects 0.000 claims 4
- 210000000232 gallbladder Anatomy 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 201000010536 head and neck cancer Diseases 0.000 claims 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims 4
- 208000014951 hematologic disease Diseases 0.000 claims 4
- 208000018706 hematopoietic system disease Diseases 0.000 claims 4
- 208000006359 hepatoblastoma Diseases 0.000 claims 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 4
- 210000004408 hybridoma Anatomy 0.000 claims 4
- 201000010260 leiomyoma Diseases 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 206010024627 liposarcoma Diseases 0.000 claims 4
- 201000007270 liver cancer Diseases 0.000 claims 4
- 208000014018 liver neoplasm Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 230000003211 malignant effect Effects 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 206010027191 meningioma Diseases 0.000 claims 4
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 4
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 4
- 201000008968 osteosarcoma Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 201000010279 papillary renal cell carcinoma Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000028591 pheochromocytoma Diseases 0.000 claims 4
- 208000010916 pituitary tumor Diseases 0.000 claims 4
- 201000002267 posterior uveal melanoma Diseases 0.000 claims 4
- 201000000849 skin cancer Diseases 0.000 claims 4
- 201000011096 spinal cancer Diseases 0.000 claims 4
- 208000014618 spinal cord cancer Diseases 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 206010042863 synovial sarcoma Diseases 0.000 claims 4
- 201000003120 testicular cancer Diseases 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 201000002510 thyroid cancer Diseases 0.000 claims 4
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 4
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 4
- 208000017997 tumor of parathyroid gland Diseases 0.000 claims 4
- 206010046766 uterine cancer Diseases 0.000 claims 4
- 208000008884 Aneurysmal Bone Cysts Diseases 0.000 claims 3
- 206010004593 Bile duct cancer Diseases 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 3
- 206010029260 Neuroblastoma Diseases 0.000 claims 3
- 201000009365 Thymic carcinoma Diseases 0.000 claims 3
- 208000008383 Wilms tumor Diseases 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 208000026900 bile duct neoplasm Diseases 0.000 claims 3
- 208000019065 cervical carcinoma Diseases 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 201000003914 endometrial carcinoma Diseases 0.000 claims 3
- 201000010103 fibrous dysplasia Diseases 0.000 claims 3
- 201000010175 gallbladder cancer Diseases 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 201000002529 islet cell tumor Diseases 0.000 claims 3
- 208000022013 kidney Wilms tumor Diseases 0.000 claims 3
- 239000003550 marker Substances 0.000 claims 3
- 201000008026 nephroblastoma Diseases 0.000 claims 3
- 208000007538 neurilemmoma Diseases 0.000 claims 3
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 claims 3
- 230000002093 peripheral effect Effects 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 208000013558 Developmental Bone disease Diseases 0.000 claims 2
- 206010072610 Skeletal dysplasia Diseases 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000008822 gestational choriocarcinoma Diseases 0.000 claims 2
- 208000030883 malignant astrocytoma Diseases 0.000 claims 2
- 206010039667 schwannoma Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 208000017234 Bone cyst Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 208000008524 alveolar soft part sarcoma Diseases 0.000 claims 1
- 230000003140 astrocytic effect Effects 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 230000035614 depigmentation Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000003619 fibrillary effect Effects 0.000 claims 1
- 208000003884 gestational trophoblastic disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 201000009500 myxoid chondrosarcoma Diseases 0.000 claims 1
- 210000003757 neuroblast Anatomy 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 201000004396 peripheral nerve schwannoma Diseases 0.000 claims 1
- 208000028528 solitary bone cyst Diseases 0.000 claims 1
- 208000017572 squamous cell neoplasm Diseases 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85811306P | 2006-11-08 | 2006-11-08 | |
| US60/858,113 | 2006-11-08 | ||
| US99388207P | 2007-09-14 | 2007-09-14 | |
| US60/993,882 | 2007-09-14 | ||
| PCT/US2007/023620 WO2008066691A2 (en) | 2006-11-08 | 2007-11-08 | Tes7 and antibodies that bind thereto |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010508847A JP2010508847A (ja) | 2010-03-25 |
| JP2010508847A5 true JP2010508847A5 (enExample) | 2011-11-04 |
| JP5601836B2 JP5601836B2 (ja) | 2014-10-08 |
Family
ID=39468449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009536307A Expired - Fee Related JP5601836B2 (ja) | 2006-11-08 | 2007-11-08 | Ｔｅｓ７およびｔｅｓ７に結合する抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7718774B2 (enExample) |
| EP (1) | EP2094307A4 (enExample) |
| JP (1) | JP5601836B2 (enExample) |
| AU (1) | AU2007325872B2 (enExample) |
| CA (1) | CA2668800A1 (enExample) |
| IL (1) | IL198592A (enExample) |
| WO (1) | WO2008066691A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007317753B2 (en) * | 2006-11-09 | 2013-11-07 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Differential gene expression in physiological and pathological angiogenesis |
| US20100203035A1 (en) * | 2007-02-14 | 2010-08-12 | Kwon Eugene D | B7-h3 in cancer |
| CN106349390B (zh) | 2008-04-02 | 2019-12-10 | 宏观基因有限公司 | Bcr-复合体-特异性抗体和其使用方法 |
| CA2731686C (en) | 2008-07-25 | 2020-04-07 | Institute For Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
| US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
| ES2525346T3 (es) | 2008-10-22 | 2014-12-22 | Institute For Research In Biomedicine | Métodos para producir anticuerpos a partir de células plasmáticas |
| JP5734201B2 (ja) | 2008-12-19 | 2015-06-17 | マクロジェニクス，インコーポレーテッド | 共有結合型ダイアボディ及びその使用 |
| TWI404931B (zh) * | 2009-02-20 | 2013-08-11 | 財團法人國家同步輻射研究中心 | 癌化生物樣本之檢測方法及其使用之檢驗試劑 |
| EP2399130A4 (en) * | 2009-02-20 | 2012-06-06 | Wayne John Cancer Inst | ASSAY OF B7-H3 ANTIBODY-COUPLED BEADS FOR THE ISOLATION AND DETECTION OF CIRCULATING TUMOR CELLS IN THE BODILY FLUIDS OF MELANOMA AND BREAST CANCER PATIENTS |
| DK2542256T3 (da) * | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| WO2012004410A1 (en) * | 2010-07-09 | 2012-01-12 | Oslo Universitetssykehus Hf | B7-h3 antagonists and taxanes |
| ES2667100T3 (es) | 2010-08-02 | 2018-05-09 | Macrogenics, Inc. | Diacuerpos covalentes y sus usos |
| EP2703486B1 (en) | 2011-04-25 | 2018-03-07 | Daiichi Sankyo Company, Limited | Anti-b7-h3 antibody |
| KR102125672B1 (ko) | 2011-04-25 | 2020-06-23 | 다이이찌 산쿄 가부시키가이샤 | 항 ｂ７-ｈ３항체 |
| US9376495B2 (en) | 2011-05-21 | 2016-06-28 | Macrogenics, Inc. | Deimmunized serum-binding domains and their use in extending serum half-life |
| HUE044089T2 (hu) | 2011-07-18 | 2019-09-30 | Inst Res Biomedicine | Neutralizáló anti-influenza A antitestek és alkalmazásaik |
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| SG11201602522VA (en) | 2013-10-02 | 2016-04-28 | Medimmune Llc | Neutralizing anti-influenza a antibodies and uses thereof |
| SG11201606714TA (en) | 2014-02-14 | 2016-09-29 | Andrew S Chi | Improved methods for the treatment of vascularizing cancers |
| WO2016011035A2 (en) | 2014-07-15 | 2016-01-21 | Medlmmune, Llc | Neutralizing anti-influenza b antibodies and uses thereof |
| MX389708B (es) | 2015-06-01 | 2025-03-20 | Medimmune Llc | Neutralizacion de moleculas de union anti-influenza y usos de las mismas. |
| UA128469C2 (uk) | 2015-10-08 | 2024-07-24 | Макродженікс, Інк. | Спосіб лікування в7-н3-експресуючого раку |
| JP2019502715A (ja) | 2016-01-13 | 2019-01-31 | メディミューン，エルエルシー | Ａ型インフルエンザを治療する方法 |
| CN109069633A (zh) | 2016-04-15 | 2018-12-21 | 宏观基因有限公司 | 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法 |
| RS61828B1 (sr) * | 2016-06-08 | 2021-06-30 | Abbvie Inc | Anti-b7-h3 antitela i antitelske konjugacije lekova |
| KR20230047507A (ko) | 2016-06-27 | 2023-04-07 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암 치료 조합 |
| CA3056474A1 (en) | 2017-03-31 | 2018-10-04 | Jiangsu Hengrui Medicine Co., Ltd. | B7-h3 antibody, antigen-binding fragment thereof and medical use thereof |
| JP7408646B2 (ja) | 2018-09-30 | 2024-01-05 | ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド | 抗－ｂ７ｈ３抗体－エキサテカンアナログコンジュゲート及びその医薬用途 |
| US12441789B2 (en) | 2019-07-11 | 2025-10-14 | Memorial Sloan Kettering Cancer Center | DLL3-targeting antibodies and uses thereof |
| US11884647B2 (en) | 2019-10-18 | 2024-01-30 | The Regents Of The University Of California | Compounds and methods for targeting pathogenic blood vessels |
| EP4045910A1 (en) * | 2019-10-18 | 2022-08-24 | The Regents of the University of California | Compositions and methods for detecting plxdc1 and plxdc2 in human tissues |
| US12590298B2 (en) | 2019-10-18 | 2026-03-31 | The Regents Of The University Of California | Ex vivo tumor angiogenesis model |
| EP4047019A4 (en) * | 2019-12-13 | 2023-11-15 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-tslp antibody and uses thereof |
| CN120093941A (zh) | 2021-02-09 | 2025-06-06 | 苏州宜联生物医药有限公司 | 生物活性物偶联物及其制备方法和用途 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3862925A (en) | 1973-07-05 | 1975-01-28 | American Home Prod | Preparation of somatotropin release inhibiting factor and intermediates therefor |
| US3842067A (en) | 1973-07-27 | 1974-10-15 | American Home Prod | Synthesis of(des-asn5)-srif and intermediates |
| JPS5726506B2 (enExample) * | 1974-03-08 | 1982-06-04 | ||
| US4105603A (en) * | 1977-03-28 | 1978-08-08 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
| USRE30548E (en) * | 1979-08-31 | 1981-03-17 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5552391A (en) | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) * | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| CA2078539C (en) * | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| ES2136092T3 (es) * | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US5532159A (en) * | 1994-04-01 | 1996-07-02 | The Ohio State University | Monoclonal antibody to canine placental oncofetal protein for detecting cancer |
| US6265150B1 (en) * | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US6440733B1 (en) * | 1996-02-15 | 2002-08-27 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibodies recognizing antigens on the surface of endothelial cells of tumor vessel |
| WO2000068266A1 (en) | 1999-05-11 | 2000-11-16 | Eli Lilly And Company | Amyloid precursor protein protease and related nucleic acid compounds |
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| US6429303B1 (en) * | 1999-09-03 | 2002-08-06 | Curagen Corporation | Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same |
| US6406840B1 (en) | 1999-12-17 | 2002-06-18 | Biomosaic Systems, Inc. | Cell arrays and the uses thereof |
| US20060154313A1 (en) * | 2000-04-13 | 2006-07-13 | Immunex Corporation | Human B7 polypeptide B7-H3A |
| WO2001089567A1 (en) | 2000-05-22 | 2001-11-29 | Idec Pharmaceuticals Corporation | Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens |
| US6965018B2 (en) * | 2000-06-06 | 2005-11-15 | Bristol-Myers Squibb Company | Antibodies directed to B7-related polypeptide, BSL-2 |
| US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| WO2002010187A1 (en) * | 2000-07-27 | 2002-02-07 | Mayo Foundation For Medical Education And Research | B7-h3 and b7-h4, novel immunoregulatory molecules |
| WO2002022683A1 (fr) * | 2000-09-12 | 2002-03-21 | Kirin Beer Kabushiki Kaisha | Nouvelle membrane a paroi cellulaire dendritique et son utilisation |
| US20030134283A1 (en) * | 2000-10-03 | 2003-07-17 | Peterson David P. | Genes regulated in dendritic cell differentiation |
| WO2002094864A2 (en) * | 2001-05-25 | 2002-11-28 | Genset S.A. | Human cdnas and proteins and uses thereof |
| US20070015144A9 (en) * | 2001-05-25 | 2007-01-18 | Genset, S.A. | Human cDNAs and proteins and uses thereof |
| US20030039999A1 (en) * | 2001-05-25 | 2003-02-27 | Amgen, Inc. | B7 related protein-2 molecules and uses thereof |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| EP1423402A4 (en) * | 2001-08-02 | 2006-07-05 | Lilly Co Eli | NOVEL ANALOGUES OF POLYPEPTIDES AND HYBRID PROTEINS AND METHODS OF USE |
| US20040162236A1 (en) * | 2002-04-01 | 2004-08-19 | John Alsobrook | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| ATE488530T1 (de) * | 2002-06-19 | 2010-12-15 | Raven Biotechnologies Inc | Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel |
| EP1534331B1 (en) | 2002-06-21 | 2014-10-29 | Johns Hopkins University School of Medicine | Membrane associated tumor endothelium markers |
| AU2003248933A1 (en) | 2002-07-11 | 2004-02-02 | Incyte Corporation | Secreted proteins |
| WO2004023973A2 (en) | 2002-09-12 | 2004-03-25 | Incyte Corporation | Molecules for diagnostics and therapeutics |
| CA2515583C (en) | 2003-03-07 | 2015-07-14 | Diversa Corporation | Hydrolases, nucleic acids encoding them and methods for making and using them |
| US20050002935A1 (en) * | 2003-04-17 | 2005-01-06 | Vincent Ling | Use of B7-H3 as an immunoregulatory agent |
| CA2463487A1 (en) * | 2003-04-28 | 2004-10-28 | Auckland Uniservices Limited | Tumours treating combinations, compositions and methods |
| US20050070474A1 (en) * | 2003-04-28 | 2005-03-31 | Krissansen Geoffrey Wayne | Methods of treatment and compositions therefor |
| WO2005017163A2 (en) | 2003-08-15 | 2005-02-24 | Imperial College Innovations Limited | Phenotypic knockout of cell-surface proteins |
| ES2381557T3 (es) | 2004-08-03 | 2012-05-29 | Innate Pharma | Métodos terapéuticos y de diagnóstico y composiciones para determinar 4IG-B7-H3 y su receptor homólogo en las células NK |
| CA2601472A1 (en) | 2005-03-08 | 2006-09-14 | Verenium Corporation | Hydrolases, nucleic acids encoding them and methods for improving paper strength |
| DK1907000T4 (da) * | 2005-06-08 | 2020-03-30 | The President And Fellows Of Harvard College | Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1). |
| EP1973572A2 (en) * | 2005-12-08 | 2008-10-01 | University of Louisville Research Foundation, Inc. | In vivo cell surface engineering |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
-
2007
- 2007-11-08 EP EP07870862.5A patent/EP2094307A4/en not_active Withdrawn
- 2007-11-08 US US11/937,470 patent/US7718774B2/en not_active Expired - Fee Related
- 2007-11-08 CA CA002668800A patent/CA2668800A1/en not_active Abandoned
- 2007-11-08 JP JP2009536307A patent/JP5601836B2/ja not_active Expired - Fee Related
- 2007-11-08 AU AU2007325872A patent/AU2007325872B2/en not_active Ceased
- 2007-11-08 WO PCT/US2007/023620 patent/WO2008066691A2/en not_active Ceased
-
2009
- 2009-05-06 IL IL198592A patent/IL198592A/en active IP Right Grant
-
2010
- 2010-03-16 US US12/724,564 patent/US8216570B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010110329A5 (enExample) | ||
| JP2005532050A5 (enExample) | ||
| JP2008529494A5 (enExample) | ||
| TWI806895B (zh) | 抗體-藥物結合物之新穎製造方法 | |
| CN111699197B (zh) | 结合cd137的单结构域抗体 | |
| JP2008532488A5 (enExample) | ||
| JP2011130770A5 (enExample) | ||
| US20260139074A1 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| TWI779386B (zh) | 抗trop2抗體及其生產方法、及抗trop2抗體-藥物結合物 | |
| JP5837567B2 (ja) | Ｍｕｃ１６に対する抗体およびその使用方法 | |
| JP2022017292A (ja) | 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体 | |
| JPWO2020122034A1 (ja) | 抗体−薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ | |
| HRP20200591T1 (hr) | Protutijela specifična za klaudin 6 (cldn6) | |
| JP2023547323A5 (enExample) | ||
| CN115698072B (zh) | 抗gpc3抗体，抗gpc3嵌合抗原受体和gpc3/cd3双特异性抗体 | |
| JP2004534020A5 (enExample) | ||
| JP2005514425A (ja) | Ｍｕｃ１８抗原に対する抗体 | |
| JP2008508858A5 (enExample) | ||
| JP2005516965A (ja) | 抗ｍｕｃ１８抗体を使用する方法 | |
| JP2012502938A5 (enExample) | ||
| JP2010535713A5 (enExample) | ||
| CN115998901A (zh) | 靶向紧密连接蛋白18.2的抗体药物偶联物 | |
| WO2007114496A1 (ja) | 新規抗ｃｄ９８抗体 | |
| JP2010531140A5 (enExample) | ||
| JP2005505256A5 (enExample) |